Crohn's Disease

Body Systems Gastrointestinal System Crohn's Disease
GI Clinical reference

Crohn's Disease

Crohn's disease is transmural granulomatous inflammation of any GI segment (skip lesions). Terminal ileum most common. Complications: fistulas, strictures, abscesses. Biologics have transformed management.

Crohn's disease Crohn disease regional enteritis granulomatous colitis
Terms
0
ICD-10
8
Evidence
0
Trials
8
Latest evidence

Latest evidence

No evidence articles returned for this search yet.

Core official overview

What this condition is

What is Crohn's disease?Crohn's disease is a chronic (long-lasting) disease that causes inflammation in your digestive tract. It can affect any part of your digestive tract, which runs from your mouth to your anus. But it usually affects your small intestine and the beginning of your large intestine.Crohn's disease is an inflammatory bowel disease (IBD). Ulcerative colitis and microscopic colitis are other common ty…

Open official source →
Condition family & coding

Terms and documentation support

Common tests

Tests performed

Common medications

Recognize the drug and the class

Related nursing diagnoses

NANDA diagnoses & care plans

Use these direct links to open nursing diagnoses and care-plan support related to Crohn's Disease.

Recruiting clinical trials

Additional official research

RECRUITING PHASE3

InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease

NCT06059989

Study Design: A Prospective Multicenter Randomized Controlled, Open-label Non-inferiority Study to Investigate the Efficacy of Subcutaneous (SC) Infliximab (IFX) with and without Immunomodulators during Induction treatment in Moderate to S…

RECRUITING NA

Behavioral Therapy for Crohn's Disease

NCT06512597

People living with Crohn's disease (CD) experience psychological and emotional symptoms, in addition to known chronic and disabling physical symptoms, which prevent them from living their life to the fullest (flourishing). Depression and a…

RECRUITING PHASE2

HB-adMSCs for the Treatment of Crohn's Disease

NCT07077746

Methodology: Randomized, double-blind, efficacy and safety study of allogeneic HB-adMSCs vs placebo for the treatment of Crohn's Disease with a 16-week treatment period and a safety and efficacy follow up period for 52 weeks post first tre…

Official education links

Plain-language study support

Useful for plain-language reinforcement and quick review.